S
Steven W. Yancey
Researcher at Research Triangle Park
Publications - 143
Citations - 9368
Steven W. Yancey is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Mepolizumab & Salmeterol. The author has an hindex of 35, co-authored 127 publications receiving 7836 citations. Previous affiliations of Steven W. Yancey include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector Ortega,Mark C. Liu,Ian D. Pavord,Guy Brusselle,J. Mark FitzGerald,Alfredo Chetta,Marc Humbert,Lynn Katz,Oliver N. Keene,Steven W. Yancey,Pascal Chanez +10 more
TL;DR: Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control and the safety profile of mepolIZumab was similar to that of placebo.
Journal ArticleDOI
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel,Sally E. Wenzel,Philip J. Thompson,Charlene M. Prazma,Oliver N. Keene,Steven W. Yancey,Hector Ortega,Ian D. Pavord +7 more
TL;DR: In this paper, a randomized, double-blind trial involving 135 patients with severe eosinophilic asthma, compared the glucocorticoid-sparing effect of mepolizumab (at a dose of 100 mg) with that of placebo administered subcutaneously every 4 weeks for 20 weeks.
Journal ArticleDOI
The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol
TL;DR: Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects and whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown.
Journal ArticleDOI
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Donald A. Mahler,James F. Donohue,Robert A. Barbee,M. Goldman,Nicholas J. Gross,Michael E. Wisniewski,Steven W. Yancey,Bradford A. Zakes,Kathleen Rickard,Wayne Anderson +9 more
TL;DR: These collective data support the use of salmeterol as first-line bronchodilator therapy for the long-term treatment of airflow obstruction in patients with COPD.
Journal ArticleDOI
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Hector Ortega,Steven W. Yancey,Bhabita Mayer,Necdet B Gunsoy,Oliver N. Keene,Eugene R. Bleecker,Christopher E. Brightling,Ian D. Pavord +7 more
TL;DR: An analysis of data from two randomised, double-blind, placebo-controlled studies of at least 32 weeks duration has shown a close relationship between baseline blood eosinophil count and clinical efficacy of mepolizumab in patients with severe eOSinophilic asthma and a history of exacerbations.